Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid

MELBOURNE, Australia, April 27, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the expansion of its...

Related Keywords

Switzerland ,United States ,Japan ,United Kingdom ,Belgium ,Australia ,Melbourne ,Victoria ,Canada ,Vienna ,Wien ,Austria ,Australian ,Michael Wheatcroft ,Mark Europe ,Thomas Beyer ,Dedicaid Gmbh ,Linkedin ,Health Canada ,Head Of The Research Domain Quantitative Imaging ,Drug Administration ,Telix Pharmaceuticals Limited ,Telix Pharmaceuticals ,Australian Securities Exchange ,University Vienna ,Telix Pharmaceuticals Limited Disclosure Committee ,Australian Therapeutic Goods Administration ,Vienna Based Dedicaid Gmbh ,Medical University ,Medical University Vienna ,United States Food ,Chief Scientist ,Research Domain ,Quantitative Imaging ,Medical Physics ,Listing Rule ,Nucl Med ,